Drug Type Small molecule drug |
Synonyms S-18886 |
Target |
Action antagonists |
Mechanism TBXA2R antagonists(Thromboxane A2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H22ClNNaO4S |
InChIKeyDSQSIJJZFSJHEW-PKLMIRHRSA-N |
CAS Registry609340-89-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Terutroban sodium | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | France | - | |
Thromboembolism | Phase 3 | United States | - | |
Thromboembolism | Phase 3 | Austria | - | |
Thromboembolism | Phase 3 | Belgium | - | |
Thromboembolism | Phase 3 | Czechia | - | |
Thromboembolism | Phase 3 | Finland | - | |
Thromboembolism | Phase 3 | France | - | |
Thromboembolism | Phase 3 | Germany | - | |
Thromboembolism | Phase 3 | Greece | - | |
Thromboembolism | Phase 3 | Hungary | - |